Telitacicept for lung disease in connective tissue disease
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a new drug called telitacicept for people with lung scarring caused by connective tissue diseases. It aims to see if the drug can improve lung function and slow down the disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a connective tissue disease like rheumatoid arthritis, lupus, Sjogren's syndrome, scleroderma, or polymyositis.
- A CT scan shows you have lung scarring (interstitial lung disease) affecting at least 10% of your lungs.
- Your lung function is moderately preserved (measured by breathing tests).
- You have been on stable treatment for your condition before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial tests a new drug called telitacicept for people who have both Sjögren's syndrome and interstitial lung disease. The drug aims to reduce the immune system's attack on your body and may help improve lung symptoms.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't improved after trying multiple treatments. It aims to see if the drug can reduce joint pain and swelling when other medications have failed.
This study tests if tetrandrine tablets can help people with lung disease caused by connective tissue disorders. It is for adults 18-80 who have stable treatment and meet specific health criteria.
This trial studies telitacicept to see if it can help keep ANCA-associated vasculitis in remission after initial treatment with steroids and rituximab. It may help prevent future flare-ups, while closely watching for side effects.
This trial tests if a new drug called telitacicept works better than a standard lupus medicine (cyclophosphamide) to improve lupus-related lung scarring (interstitial lung disease). It might be an option if your breathing tests are still good enough.
This trial tests a new drug called telitacicept for people with recently diagnosed, rapidly progressing systemic sclerosis (scleroderma). It aims to see if the drug can slow down skin thickening and other symptoms.
Hear when a new CTD-ILD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.